4.7 Article

Benzodiazepine, psychotropic medication, and dementia: A population-based cohort study

期刊

ALZHEIMERS & DEMENTIA
卷 12, 期 5, 页码 604-613

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2015.10.006

关键词

Cohort studies; Alzheimer's disease; Dementia; Benzodiazepine; Psychotropic medication

资金

  1. Fondation Plan Alzheimer
  2. Caisse Nationale Maladie des Travailleurs Salaries
  3. Direction Generale de la Sante
  4. MGEN
  5. Institut de la Longevite
  6. Conseils Regionaux of Aquitaine and Bourgogne
  7. Fondation de France
  8. Ministry of Research-INSERM Programme Cohortes et collections de donnees biologiques
  9. Fondation pour la Recherche Medicale

向作者/读者索取更多资源

Introduction: Benzodiazepine use has been associated with increased risk of dementia. However, it remains unclear whether the risk relates to short or long half-life benzodiazepines and whether it extends to other psychotropic drugs. Methods: Prospective cohort study among 8240 individuals >= 65, interviewed on medication use. Incident dementia confirmed by an end point committee after a multistep procedure. Results: During a mean of 8 years of follow-up, 830 incident dementia cases were observed. Users of benzodiazepines at baseline had a 10% increased risk of dementia (adjusted hazard ratio [HR], 1.10; 95% confidence interval, 0.90-1.34). However, long half-life (>20 hours) benzodiazepine users had a marked increased risk of dementia (HR = 1.62; 1.11-2.37) compared with short half-life users (HR = 1.05; 0.85-1.30). Users of psychotropics had an increased risk of dementia (HR = 1.47; 1.16-1.86). Discussion: Results of this large, prospective study show increased risk of dementia for long half-life benzodiazepine and psychotropic use. (C) 2015 Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据